Lantus/Lixisenatide Combo Gets FDA Panel Nod, But Not Sanofi's Device
This article was originally published in The Pink Sheet Daily
Executive Summary
Pen for iGlarLixi should be redesigned to reduce risk of confusion and medication errors, advisory committee members say.